Patient-derived cell models as preclinical tools for genomedirected targeted therapy

Oncotarget

Volumn 6, Issue 28, 2015, Pages 25619-25630

  Lee, Ji Yun ^a   Kim, Sun Young ^a   Park, Charny ^a   Kim, Nayoung K D ^b   Jang, Jiryeon ^a   Park, Kyunghee ^b   Yi, Jun Ho ^d   Hong, Mineui ^a,b   Ahn, Taejin ^b   Rath, Oliver ^c   Schueler, Julia ^c   Kim, Seung Tae ^a   Do, In Gu ^a   Lee, Sujin ^a   Park, Se Hoon ^a   Ji, Yong Ick ^a   Kim, Dukwhan ^a   Park, Joon Oh ^a,b   Park, Young Suk ^a   Kang, Won Ki ^a   Kim, Kyoung Mee ^a,b   Park, Woong Yang ^a,b   Lim, Ho Yeong ^a   Lee, Jeeyun ^a,b   more..

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c CHARLES RIVER LABORATORIES   (United States)

^d Hanyang University College of Medicine   (South Korea)

Author keywords

Gastric cancer; Genomic analysis; Patient derived cells; Targeted therapy

Indexed keywords

LAPATINIB; SORAFENIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT ASCITES; MALIGNANT PLEURA EFFUSION; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; STOMACH CANCER; TUMOR XENOGRAFT; ANIMAL; ASCITES FLUID; DRUG SCREENING; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN GENOME; MALE; MIDDLE AGED; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE; PRIMARY CELL CULTURE; PROCEDURES; TUMOR CELL CULTURE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; ASCITIC FLUID; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HUMANS; MALE; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; PATIENT SELECTION; PHENOTYPE; PLEURAL EFFUSION, MALIGNANT; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PRIMARY CELL CULTURE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84944463697     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4627     Document Type: Article

References (30)

1. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006; 6:813-823.
2. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, Scudiero DA, Weinstein JN, Kirsch IR. Karyotypic complexity of the NCI-60 drugscreening panel. Cancer Res. 2003; 63:8634-8647.
3. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A. 2011; 108:18708-18713.
4. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004; 432:332-337.
5. Ostman A, Augsten M. Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev. 2009; 19:67-73.
6. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001; 84:1424-1431.
7. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, Watkins DN. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009; 69:3364-3373.
8. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011; 17:1514-1520.
9. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012; 14:R11.
10. Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol. 2010; 12:473-480.
11. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008; 1:78-82.
12. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Maelandsmo GM, Roman-Roman S, Seoane J, Trusolino L, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014; 4:998-1013.
13. Junttila MR, de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature. 2013; 501:346-354.
14. Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol. 2013; 31:347-354.
15. Kim S, Lee J, Hong ME, Do IG, Kang SY, Ha SY, Kim ST, Park SH, Kang WK, Choi MG, Lee JH, Sohn TS, Bae JM, et al. High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PLoS One. 2014; 9:e111693.
16. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22:568-576.
17. Ramos AH, Lichtenstein L, Gupta M, Lawrence MS, Pugh TJ, Saksena G, Meyerson M, Getz G. Oncotator: cancer variant annotation tool. Hum Mutat. 2015; 36:E2423-2429.
18. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, James JJ, Maysuria M, Mitton JD, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26:317-325.
19. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513:202-209.
20. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, Ye XS, Do IG, Liu S, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21:449-456.
21. Chen C, Grennan K, Badner J, Zhang D, Gershon E, Jin L, Liu C. Removing batch effects in analysis of expression microarray data: an evaluation of six batch adjustment methods. PLoS One. 2011; 6:e17238.
22. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res. 2003; 9:4227-4239.
23. Fleming JM, Miller TC, Meyer MJ, Ginsburg E, Vonderhaar BK. Local regulation of human breast xenograft models. J Cell Physiol. 2010; 224:795-806.
24. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013; 73:5315-5319.
25. Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer. 2004; 40:827-836.
26. Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, Hong YS, Do IG, Jang J, Thorner AR. Van Hummelen P, Rustgi AK, Wong KK, et al. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest. 2014; 124:5145-5158.
27. Ha SY, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, et al. HER2-positive gastric cancer with concomitant MET and/ or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. Int J Cancer. 2015; 136:1629-1635.
28. Yi JH, Jang J, Cho J, Do IG, Hong M, Kim ST, Kim KM, Lee S, Park SH, Park JO, Park YS, Kang WK, Lim HY, et al. MerTK is a novel therapeutic target in gastric cancer. Oncotarget. 2015. Apr 20. PMID: 25965821. [Epub ahead of print].
29. Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol. 2005; 15:365-377. 30. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007; 130:601-610.
30. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007; 130:601-610